<?xml version="1.0" encoding="UTF-8"?>
<p id="Par13">The study enrolled 49 heavily pretreated patients with relapsed or refractory B-cell NHL (median of 3 prior systemic regimens [range, 1–13]), including those who had previously undergone radiation and/or autologous stem cell transplant (Table 
 <xref rid="Tab1" ref-type="table">1</xref>). The population had a median age of 65 years, was primarily male (65%), and consisted of individuals with DLBCL (49%), FL (29%), MCL (14%), or MZL (8%). Twenty-eight patients (57%) received 3 or more cycles of IMGN529 therapy (range 1–16).
</p>
